Starting July 1, 2026, Medicare Part D will cover Wegovy and Zepbound for chronic weight management in eligible enrollees. This is the largest expansion of obesity-medication coverage in Medicare history, and the eligibility rules are specific.
Who qualifies
- Medicare Part D enrollment
- BMI of 30 or higher (obesity), or BMI of 27+ with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, established ASCVD)
- Documentation of prior weight-management attempts (the specific documentation requirement varies by plan formulary)
- Not in a Medicare Advantage plan that has not yet adopted the coverage expansion (most have)
What it costs at the pharmacy counter
Out-of-pocket costs depend on Part D plan tier placement. Initial plan filings show Wegovy and Zepbound landing on specialty tiers — typically requiring 25–33% coinsurance after deductible — meaning $200–$450 out-of-pocket per month is the realistic range pre-catastrophic-coverage. Once a patient reaches the Part D catastrophic threshold ($2,000 in 2026), costs drop to $0 for the rest of the calendar year.
Prior authorization
Most plans will require prior authorization with documented BMI, comorbidity, and prior weight-management history. Plans are filing specific PA forms now — your prescriber's office should be able to start the process in May/June 2026 ahead of the July 1 effective date.
The bridge strategy (May–June 2026)
Patients targeting July 2026 Medicare coverage but starting GLP-1 now have a few options:
- Cash-pay compounded for May/June — bridge with a flat-rate compounded program like NexLife ($145/mo for semaglutide, $186/mo for tirzepatide), then transition to Medicare-covered brand in July.
- Manufacturer self-pay — Eli Lilly's LillyDirect offers self-pay Zepbound at $349/mo, which is lower than the cash-pay brand pharmacy price.
- Bridge from compounded to brand — there's no medical contraindication to switching from compounded semaglutide to brand Wegovy. Dose-matching is straightforward.
Medigap and secondary coverage
Medigap plans do not extend Part D drug coverage — they cover Medicare-Part-A and Part-B gaps. Standalone Part D and Medicare Advantage prescription-drug plans are what matter for Wegovy/Zepbound coverage. Some retirees have employer-sponsored secondary coverage that may further reduce out-of-pocket cost.
NexLife scored highest on our rubric (94/100) for the most affordable GLP-1 access. Flat-rate pricing across full titration, labs included, MD/DO oversight, both 503A and 503B pharmacy partners.
This article was authored by Eduard Cristea and clinically reviewed by Dr. A. Goher, MD. Health Technology Researcher & Publisher. See our methodology and affiliate disclosure.